Mycophenolate Mofetil Dosing for 55 kg Adult
For a 55 kg adult, the appropriate mycophenolate mofetil dose depends on the indication: for renal transplant, use 1 g twice daily (2 g/day total); for cardiac or hepatic transplant, use 1.5 g twice daily (3 g/day total); for lupus nephritis maintenance therapy, use 750-1000 mg twice daily. 1
Transplant Indications
The FDA-approved dosing is standardized by organ type rather than body weight 1:
- Renal transplant: 1 g orally twice daily (2 g/day total dose)
- Cardiac transplant: 1.5 g orally twice daily (3 g/day total dose)
- Hepatic transplant: 1.5 g orally twice daily (3 g/day total dose)
For a 55 kg patient receiving renal transplant, the standard 1 g twice daily translates to approximately 18 mg/kg/day, which falls within the optimal range suggested by pharmacokinetic studies 2, 3.
Important Caveats for Transplant Patients
Severe chronic renal impairment (GFR <25 mL/min/1.73 m²) outside the immediate post-transplant period requires dose reduction—avoid doses greater than 1 g twice daily and monitor carefully 1.
Delayed graft function does not require dose adjustment, though MPAG (the inactive metabolite) accumulates 2-3 fold 1. However, MPA exposure remains comparable to patients without delayed function.
Neutropenia (ANC <1.3 × 10³/µL) mandates dose interruption or reduction 1.
Lupus Nephritis
For lupus nephritis maintenance therapy after completing initial treatment, the recommended dose of mycophenolate mofetil is 750-1000 mg twice daily 4. This translates to approximately 27-36 mg/kg/day for a 55 kg patient, which is higher than transplant dosing.
The corresponding mycophenolic acid (enteric-coated formulation) dose would be 540-720 mg twice daily 4.
Weight-Based Dosing Considerations
While FDA labeling uses fixed dosing, pharmacokinetic data reveals important nuances:
Lower body weight patients achieve higher drug exposure per mg of MMF 2, 3. Research shows that patients with lower body weight tend to have higher MPA AUC:MMF dose ratios. For a 55 kg patient, the standard 1 g twice daily dose (approximately 18 mg/kg/day) should achieve therapeutic MPA exposure of 30-60 μg·h/mL 2.
MMF exhibits nonlinear pharmacokinetics—bioavailability decreases with increasing doses 5. This means doubling the dose does not double the drug exposure, which is particularly relevant when considering dose adjustments.
Administration Recommendations
- Administer on an empty stomach when possible (food decreases peak concentration by 40%, though total exposure is unchanged) 1
- In stable renal transplant patients, may give with food if necessary
- Dosing frequency matters: every 8-hour dosing maintains higher plasma levels than every 12-hour dosing, even at the same total daily dose 6
Monitoring Strategy
Given the wide pharmacokinetic variability and nonlinear dose-response relationship, therapeutic drug monitoring is valuable. Target MPA AUC of 30-60 μg·h/mL for transplant patients. For a 55 kg patient on standard dosing, this target should be achievable, but individual variation necessitates monitoring if clinical response is suboptimal 2, 5.